Proton Therapy Opens at Sibley Memorial Hospital, a Member of Johns Hopkins Medicine, US top ranked healthcare institution
Tokyo, October 29, 2019 --- Hitachi, Ltd. (TSE:6501, “Hitachi”) today announced that Hitachi has provided its advanced proton therapy system to Sibley Memorial Hospital (Washington DC, US), a member of Johns Hopkins Medicine (Maryland, US), and it has started treatment on October 25, 2019. On October 28, an opening ceremony at Sibley Memorial Hospital was held.
The proton therapy system installed at Sibley includes spot scanning technology that sends a therapeutic proton beam precisely conforming to the shape of the target tumor. It has three rotating gantry treatment rooms and one fixed beam research room. This is the first Hitachi system in the US with Real-time Gated Proton Therapy capability, which allows real-time beam irradiation to the tumor while compensating for movement associated with respiration.
Johns Hopkins Medicine, based in Baltimore, Maryland, US, is a world-class hospital focusing on medical research and clinical care. Johns Hopkins Hospital has maintained its position as one of top hospitals in U.S. News & World Report rankings for decades. Sibley Memorial Hospital, an affiliate of Johns Hopkins Medicine, provides cancer care from the world-renowned Johns Hopkins Sidney Kimmel Comprehensive Cancer Center which also has one of the most successful cancer research programs in the world.
Hitachi has been proactively promoting particle therapy system business worldwide, supplying world-class facilities with its highly reliable and proven particle therapy systems, which have treated more than 60,000 patients. Hitachi will provide system and services, including single room solution in realizing installation in urban limited areas and hybrid system combined with capability of generating both proton and heavy ion in one accelerator, to meet all customer needs.
Hitachi will continue to accelerate the globalization of its particle therapy system business and contribute to cancer treatment around the world.
* U.S. News & World Report releases its Best Hospitals rankings in the country every year.
Particle Therapy is an advanced type of cancer radiotherapy. Protons extracted from hydrogen atoms, or carbon ions are accelerated up to 70% of the speed of light. This energy is concentrated directly on the tumor while minimizing radiation dose to surrounding healthy tissue. Particle therapy improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared to that of traditional radiotherapy. In most cases, patients can continue with their normal daily activities while undergoing treatment.
For more information on Hitachi’s Particle Therapy System
Hitachi America, Ltd. headquartered in Santa Clara, CA, a subsidiary of Hitachi, Ltd., and its subsidiary companies offer a broad range of electronics, power and industrial equipment and services, particle beam therapy technologies, automotive products and consumer electronics with operations throughout the Americas. For more information, visit http://www.hitachi-america.us/. For information on other Hitachi Group companies in the United States, please visit http://www.hitachi.us/.
Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, is focusing on Social Innovation Business combining its operational technology, information technology and products. The company’s consolidated revenues for fiscal 2018 (ended March 31, 2019) totaled 9,480.6 billion yen ($85.4 billion), and the company has approximately 296,000 employees worldwide. Hitachi delivers digital solutions utilizing Lumada in five sectors including Mobility, Smart Life, Industry, Energy and IT, to increase our customer’s social, environmental and economic value. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.
Hitachi America, Ltd.